The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 25, 2025
Filed:
Feb. 19, 2020
Applicant:
Memorial Sloan-kettering Cancer Center, New York, NY (US);
Inventors:
Michel Sadelain, New York, NY (US);
Fabiana Perna, New York, NY (US);
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/72 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); G01N 33/566 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); G16B 5/00 (2019.01); G16B 20/00 (2019.01); G16B 20/20 (2019.01); G16B 20/30 (2019.01); G16B 20/50 (2019.01); G16B 30/00 (2019.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464429 (2023.05); A61K 39/464431 (2023.05); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 14/70575 (2013.01); C07K 14/7158 (2013.01); C07K 14/723 (2013.01); C07K 16/00 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); G01N 33/566 (2013.01); G01N 33/56972 (2013.01); G01N 33/6845 (2013.01); G16B 5/00 (2019.02); G16B 20/00 (2019.02); G16B 20/20 (2019.02); G16B 20/30 (2019.02); G16B 20/50 (2019.02); G16B 30/00 (2019.02); A61K 2039/804 (2018.08); A61K 48/00 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/70 (2013.01); G06F 2218/00 (2023.01);
Abstract
The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.